1
-

1	Ex-PRESS implantation versus trabeculectomy for long-term maintenance of low
2	intraocular pressure in patients with open angle glaucoma
3	
4	Short title: Ex-PRESS implantation versus trabeculectomy for low intraocular pressure
5	maintenance
6	
7	Kana Tokumo1*, Naoki Okada, Hiromitsu Onoe, Kaori Komatsu, Shun Masuda, Hideaki
8	Okumichi, Kazuyuki Hirooka, Ryo Asaoka, Yoshiaki Kiuchi,
9	<sup>1</sup> Department of Ophthalmology and Visual Science, Hiroshima University Graduate School of
10	Biomedical Sciences Hiroshima University, Hiroshima, Japan
11	<sup>2</sup> Seirei Hamamatsu General Hospital Department of Ophthalmology, Shizuoka, Japan
12	
13	*Corresponding author
14	E-mail: kanatokumo@ hiroshima-u.ac.jp (KT) ORCID: https://orcid.org/0000-0001-5147-4829
15	
16	Authors' contributions
17	All authors contributed to the study conception and design. Material preparation, data collection,
18	and data analysis were performed by Kana Tokumo and Shun Masuda. The first draft of the
19	manuscript was written by Kana Tokumo. All authors commented on the previous versions of
20	the manuscript. All authors read and approved the final manuscript.
21	
22	Registry

2

- 23 This study was registered with the University Hospital Medical Information Network Clinical
- 24 Trials Registry of Japan (identifier University Hospital Medical Information Network
- 25 000008981; date of access and registration, September 25, 2012
- 26
- 27

# 28 Abstract

29 **Purpose**: To compare the efficacy of Ex-PRESS implantation to trabeculectomy with mitomycin

30 C, for maintaining low target intraocular pressure (IOP) in patients with open angle glaucoma.

31 Materials and Methods: Patients were randomly assigned to receive Ex-PRESS implantation or

32 trabeculectomy. Patients with  $IOP \ge 15$  mmHg were included in this study. Surgical success was

defined according to three target mean IOP ranges (5 mmHg  $\leq$  IOP  $\leq$ 18 mmHg [criterion A], 5

34 mmHg  $\leq$  IOP  $\leq$ 15 mmHg [criterion B], and 5 mmHg  $\leq$  IOP  $\leq$ 12 mmHg [criterion C])

35 representing reductions of at least 20% below baseline on two consecutive follow-up visits 3

36 months post surgery.

37 **Results**: A total of 73 patients, including 30 in the Ex-PRESS implantation group and 43 in the 38 trabeculectomy group, were included in the study. The baseline IOP was  $20.4 \pm 4.9$  mmHg in the 39 Ex-PRESS implantation group and  $21.9 \pm 7.9$  mmHg in the trabeculectomy group. There were 40 no significant differences in baseline ocular or demographic characteristics between the two 41 groups. There was no statistical difference in IOP every 6 months. After the 3-year follow-up, 42 success rates were A) 60.0% and 60.2%, B) 45.7% and 58.1%, and C) 31.5% and 40.5% for the 43 Ex-PRESS implantation and trabeculectomy groups, respectively. A greater number of glaucoma 44 medications before surgery was associated with a higher failure rate in the trabeculectomy group 45 but not the Ex-PRESS implantation group.

- 46 **Conclusions**: Both procedures resulted in similar IOP reductions and success rates for low target
- 47 IOP. The number of preoperative glaucoma medications was a risk factor for trabeculectomy
- 48 failure.

49

It is made available under a CC-BY 4.0 International license .

# 50 Introduction

Filtering surgery is widely used for the treatment of glaucoma with uncontrollable intraocular
pressure (IOP). Currently, the most popular filtering surgery is trabeculectomy (TLE), in which
aqueous humor filtration is enhanced and IOP reduced by creating a scleral flap that leads to bleb
formation in the conjunctiva. The success and complication rates for TLE are well established
[1-2].

56 The Ex-PRESS glaucoma filtration device (Alcon Laboratories, Fort Worth, TX, USA) was 57 introduced as a modification to TLE. Although the surgical procedure and postoperative 58 management is similar to TLE, Ex-PRESS (EXP) surgery does not require sclerectomy or 59 iridectomy. Therefore, postoperative inflammation and hemorrhage may be reduced. Both 60 surgical procedures can achieve similar IOP reductions with few complications when the target 61 pressure is set to 18 mmHg [3-5]. However, the optimal target IOP for glaucoma treatment 62 depends on disease stage, IOP before treatment, age, and other risk factors. In general, more 63 severe glaucoma requires lower IOP post surgery to maintain visual function [6-8]. 64 The success of TLE depends on preoperative IOP, previous surgery, number of preoperative 65 medications, and race [9]. There is a high incidence of normal tension glaucoma (NTG) in the 66 Japanese population [10], and visual field impairment in subjects with NTG often progresses 67 even when IOP is within the normal range. Therefore, NTG patients may benefit from a 68 postoperative target pressure below that of patients with higher preoperative IOP.

69 This study compared the efficacy and safety of EXP to TLE for achieving target postoperative
70 IOPs of ≤18, ≤15, and ≤12 mmHg, each representing reductions of at least 20% below baseline,

It is made available under a CC-BY 4.0 International license .

5

- among patients in the Japanese population with open angle glaucoma (OAG, includingexfoliation glaucoma and primary OAG).
- 73

# 74 Materials and methods

The institutional review board of Hiroshima University approved the study protocol before
recruitment. This study was registered with the University Hospital Medical Information
Network Clinical Trials Registry of Japan (identifier University Hospital Medical Information
Network 000008981; date of access and registration, September 25, 2012). All patients provided
written informed consent before participation, and the study was conducted in accordance with
the tenets of the Declaration of Helsinki.

81

#### 82 Randomization and treatment

83 The study was conducted at the Department of Ophthalmology, Hiroshima University Hospital. 84 Patients were enrolled between November 2012 and March 2015. Follow-up was done for one 85 year, three years if possible. Patients were randomized to receive TLE or EXP using a computer-86 based random number generator. Clinicians enrolled participants to this study. Random 87 allocation were prepared by staff not associated with this study and he assigned participants to 88 interventions. It was confirmed after patient enrollment is completed which surgery will be 89 performed. Both patients and clinicians were aware of the therapy (therefore, this was an open-90 label, randomized study).

91

#### 92 Patients and inclusion criteria

This was a single-center clinical trial of OAG patients > 20 years and older with or without
cataract scheduled for filtration surgery. Patients who previously underwent glaucoma surgery
were excluded. However, subjects who underwent cataract surgery more than 6 months prior to
planned TLE or EXP were included. We analyzed the first eye when both eyes met the inclusion
criteria. Subjects with preoperative IOP < 15 mmHg were excluded after randomization, and</li>
their data were analyzed in another study.

99

#### 100 **Outcome measures**

101 Goldman applanation tonometry was used to measure the IOP. Preoperative IOP and best-

102 corrected visual acuity (VA) were recorded during the examination immediately before surgery.

103 We documented the IOP and VA the day after surgery and at every follow-up visit. Postoperative

104 IOP and VA values measured every six months for three years were included in the efficacy

105 (surgical success) analysis. The surgical procedures and postoperative management were similar

106 for each case.

107 Anesthesia included subconjunctival 2% lidocaine injection. A limbal-based conjunctival flap

108 was utilized, followed by the creation of a half-thickness scleral flap. Small pieces of gelatin

sponge soaked with 0.4 mg/mL mitomycin C (MMC) was applied to the exposed tissue,

110 including the posterior surface of Tenon's capsule and conjunctiva, adjacent episcleral tissue,

and scleral flap for 5 min. After 5 min, all sponges were removed, and the wound was irrigated

112 with 100 mL of balanced salt solution. For patients assigned TLE, a block incision was made in

- 113 the region of the trabecular meshwork, followed by peripheral iridectomy. For those patients
- 114 randomized to receive EXP, a small scleral tunnel was created as a shunt in the region of the

It is made available under a CC-BY 4.0 International license .

trabecular meshwork using a 25-G needle. The scleral flap and conjunctiva were closed with 10-

116 0 nylon sutures.

- 117 Patients were treated with laser suture lysis if IOP was higher than the target IOP. The target IOP
- 118 for most patients was set at 8–10 mmHg 2 weeks postoperatively.<sup>8</sup>
- 119 All patients received a similar topical medical regimen, including postoperatively: 1.5%
- 120 levofloxacin and 0.1% topical betamethasone three times per day. Patients receiving combined
- 121 cataract surgery were also administered nepafenac three times a day. Topical atropine sulfate
- 122 (1%) was used as needed. All doses were tapered at the surgeon's discretion.
- 123

#### 124 Parameters for surgical success

125 The primary outcome was surgical success based on target postoperative IOP range at 6-month 126 intervals with or without antiglaucoma medications according to guidelines by the World 127 Glaucoma Association [11]. There were three target IOP ranges: (A) 5 mmHg  $\leq$ IOP  $\leq$ 18 mmHg, 128 (B) 5 mmHg  $\leq$ IOP  $\leq$ 15 mmHg, and (C) 5 mmHg  $\leq$ IOP  $\leq$ 12 mmHg. Failure was defined as an 129 IOP above the indicated range on two consecutive follow-up visits 3 months after surgery and a 130 reduction of less than 20% below baseline, or the need for further glaucoma surgery. The need 131 for laser suture lysis or bleb needling was not considered surgical failure as these procedures are 132 part of routine postoperative management for filtration surgeries.

133

#### 134 Statistical analysis

- 135 All statistical analyses were performed using JMP version 15 (Cary, North Carolina, USA).
- 136 Results are presented as mean  $\pm$  standard deviation (SD) unless otherwise indicated. Mean values

137 of normally distributed continuous variables were compared between groups by Student's t-test 138 and proportion (e.g., of patients with visual stability or surgical success) by chi-square test. 139 Measured IOP values were compared using the Mann–Whitney nonparametric test with 140 Bonferroni correction for repeated measures. Patients requiring additional surgery were censored 141 from the analysis after reoperation. Success rates were analyzed over time using Kaplan-Meier 142 survival curves. The survival data were analyzed using regression analysis based on the Cox 143 proportional hazards model. All statistical tests were two-sided, and P-values <0.05 were 144 considered statistically significant. A sample size calculation determined that 30 eyes in each 145 group were required to detect a 2.5-mmHg difference in IOP with an SD of 2.75 mmHg and 146 power of 80%. To account for patient dropout, 73 eyes were included.

147

#### 148 **Results**

149 A total of 105 patients with OAG (105 eyes) were enrolled in the study. Two patients who had 150 glaucoma surgery were excluded. After randomization, 30 patients whose preoperative IOP was 151 <15 mmHg were excluded. Thirty eyes were treated with EX-PRESS implantation (EXP group) 152 and 43 eyes with TLE (TLE group). The number of patients who could be followed is shown in 153 Fig 1. Patients who had mild to severe cataract underwent combined cataract surgery. All 154 patients were Japanese. Patient demographics and basic characteristics are summarized in Table 155 1. The mean follow-up period was  $25.9 \pm 12.9$  months in the EXP group and  $23.8 \pm 13.1$  months 156 in the TLE group. No differences were found in baseline IOP, sex ratio, age, and number of 157 glaucoma medications between EXP and TLE groups.

158

It is made available under a CC-BY 4.0 International license .

			9
Characteristics	<b>EXP group (n = 30)</b>	TLE group (n = 43)	<b>P-values</b>
Age (years), mean ± SD	68.3 ± 11.9	68.7 ± 12.4	0.90*
Sex, n (%)			0.64†
Male	17 (56.7)	22 (51.2)	
Female	13 (43.3)	21 (48.8)	
IOP (mmHg), mean $\pm$ SD	$20.4 \pm 4.9$	21.9 ± 7.9	0.84‡
Glaucoma medications, n, mean $\pm$ SD	3.1 ± 0.8	3.3 ± 0.8	0.44*
Follow-up period (months), mean ± SD	25.9 ± 12.9	23.8 ± 13.1	0.50*
Previous cataract surgery, n (%)	11(36.7)	11 (19.6)	0.31*
Surgery (%)			0.59†
Glaucoma surgery alone	22 (73.3)	29 (67.4)	
Combined glaucoma and cataract surgery	8 (26.7)	14 (32.6)	

#### 159 Fig 1. Flowchart of follow-up.

- 160 Table 1. Baseline demographics and ocular characteristics of the EXP group (30 eyes) and TLE
- 161 group (43 eyes).
- 162 EXP, Ex-PRESS; IOP, intraocular pressure; LogMAR, logarithm of the minimal angle of
- 163 resolution; SD, standard deviation; TLE, trabeculectomy
- 164 \*Student's t-tests
- 165 <sup>‡</sup>Mann–Whitney nonparametric tests
- 166 <sup>†</sup>Pearson chi-square tests
- 167

# 168 **IOP reduction**

It is made available under a CC-BY 4.0 International license .

169	The mean IOP	at each postoper	ative visit is presented i	n Table 2 and shown	graphically	in Fig 2.
-----	--------------	------------------	----------------------------	---------------------	-------------	-----------

- 170 Both surgical procedures led to a significant sustained reduction in IOP. In the EXP group, the
- 171 IOP decreased from  $20.4 \pm 4.9$  to  $13.2 \pm 1.9$  mmHg at the 3-year follow-up visit (P = 0.001,
- paired t-tests). In the TLE group, the IOP decreased from  $21.9 \pm 7.9$  to  $13.5 \pm 5.0$  mmHg at the 3-
- 173 year follow-up visit (P = 0.0012, paired t-tests). Both surgical procedures resulted in a significant
- 174 reduction in IOP after surgery compared to the preoperative IOP. There were no differences in
- 175 IOP between the two groups during observation.
- 176 Kaplan–Meier survival analysis was used to compare success rates between the two treatment
- 177 groups. We created three definitions of success and compared the survival curves. At the 1-year
- 178 follow-up, the success rates of EXP and TLE were 72.0% and 70.8%, 65.3% and 68.3%, and
- 179 55.1% and 58.5% for criteria A, B, and C, respectively. At the 3-year follow-up, success rates of
- 180 EXP and TLE were 60.0% and 60.2%, 45.7% and 58.1%, and 31.5% and 40.5% for criteria A, B,
- 181 and C, respectively (Fig 3).
- 182 No significant differences in treatment efficacy were found between strata (A, P = 0.93; B, P =
- 183 0.53; C, P = 0.58, log-rank test).
- 184

185	Table 2. Mean	intraocular	pressure and	medication us	se.

	EXP group (n = 30)	TLE group (n = 43)	P-values
Baseline IOP (mmHg)	$20.4 \pm 4.9$	21.9 ± 7.9	0.84‡
Glaucoma medications, n	3.1 ± 0.8	3.3 ± 0.8	0.44*
6 months			
IOP (mmHg)	12.0 ± 3.9	11.2 ± 2.9	0.46‡
Glaucoma medications, n	0.3 ± 0.8	$0.2 \pm 0.8$	0.83*

It is made available under a CC-BY 4.0 International license .

11

12 months			
IOP (mmHg)	12.1 ± 3.5	$12.4 \pm 4.3$	0.68‡
Glaucoma medications, n	0.5 ± 1.2	0.6 ± 1.3	0.82*
18 months			
IOP (mmHg)	12.8 ± 3.9	$12.8 \pm 4.7$	0.82‡
Glaucoma medications, n	$1.2 \pm 1.5$	1.0 ± 1.5	0.70*
24 months			
IOP (mmHg)	13.2 ± 3.3	13.1 ± 4.5	0.68‡
Glaucoma medications, n	1.5 ± 1.7	1.1 ± 1.5	0.52*
30 months			
IOP (mmHg)	15.5 ± 5.5	$13.4 \pm 4.3$	0.15‡
Glaucoma medications, n	1.7 ± 1.9	1.0 ± 1.5	0.29 *
36 months			
IOP (mmHg)	13.2 ± 1.9	$13.5 \pm 5.0$	0.91‡
Glaucoma medications, n	$2.2 \pm 1.3$	$1.2 \pm 1.5$	0.04*

- 186 EXP, Ex-PRESS; IOP, intraocular pressure; TLE, trabeculectomy
- 187 Data are presented as mean  $\pm$  SD, unless otherwise indicated.
- 188 \*Student t-tests
- 189 *Based on Mann–Whitney nonparametric tests with Bonferroni correction, P-values <0.0083*
- 190 were statistically significant.
- 191

192 Fig 2. IOP (in mmHg) for the EXP (30 eyes) and TLE groups (43 eyes) from the preoperative

193 visit to the 3-year follow-up visit (mean ± SD).

12

Fig 3. Kaplan–Meier survival curves of surgical outcomes for eyes in the EXP (30 eyes; solid
line) and TLE groups (43 eyes; dotted line).

196

### 197 Glaucoma medication use

The mean number of glaucoma medications required at each postoperative visit is shown in
Table 2. Both groups required significantly fewer glaucoma medications after surgery, with no
significant differences between groups. The EXP group required more postoperative eye drops
than the TLE group. The difference increased gradually with time.

202

#### 203 Visual acuities

204 Decimal VA was converted to logarithm of minimum angle of resolution equivalents (logMAR) 205 for statistical analysis. All patients who underwent glaucoma surgery combined with cataract 206 surgery showed improvement in VA, so these patients were excluded from VA analysis. Fig 4 207 shows the VA results 1 year after glaucoma surgery. LogMAR VA did not differ significantly 208 between the groups immediately after the procedure  $(0.30 \pm 0.60$  in the EXP group and  $0.14 \pm$ 209 0.33 in TLE group, P = 0.20 by Mann–Whitney U-test), at 1 year post surgery (0.37 ± 0.61 in the 210 EXP group and  $0.20 \pm 0.43$  in TLE group, P = 0. 24 by Mann–Whitney U-test) or 3 years post 211 surgery (0.44  $\pm$  0.55 in the EXP group and 0.33  $\pm$  0.52 in TLE group, P = 0.34 by Mann-212 Whitney U-test). Six patients in each group lost more than two lines at the last visit, while one 213 subject in the TLE group developed cataract, which resulted in a decrease in VA. The others lost 214 their vision due to glaucoma progression.

215

- Fig 4. Scatterplot comparing VA (logMAR) values at baseline and 1-year visit for individual
  patients in the EXP (30 eyes; circular dots) and TLE groups (43 eyes; diamond dots).
- 218

# 219 **Postoperative complications**

- Table 3 shows complications of the two groups in the early and late postoperative periods. At the
- first month postoperatively, 13 patients in the EXP group and 10 patients in the TLE group
- developed early complications. These included hyphema, choroidal detachment, shallow anterior
- 223 chamber, hypotony maculopathy, and conjunctiva leakage. Both groups showed similar
- 224 complications. There was no statistically significant difference in the total prevalence of early-
- phase complications between groups (P = 0.07 Student t-test). Only the TLE group showed late-
- 226 phase postoperative complications, one case of choroidal detachment and one of conjunctiva
- 227 leakage. However, there was no statistically significant difference in the prevalence of late-phase
- 228 complications between groups (P = 0.27 by Student's t-test).
- 229
- Table 3. Early postoperative complications and late postoperative complications.

It is made available under a CC-BY 4.0 International license .

	EXP group n (%)	TLE group n	
		(%)	P-values†
Early postoperative complication			
Hyphema	4 (13.3)	2 (4.7)	0.18
Shallow anterior chamber	5 (16.7)	6 (14.0)	0.70
Choroidal detachment	6 (20.0)	4 (9.3)	0.19
Conjunctiva leakage	5 (16.7)	4 (9.3)	0.35
Hypotony maculopathy	0	1 (2.3)	0.40
Total number of complications	13 (43.3)	10 (23.3)	0.07
Late postoperative complications			
Hyphema	0	0	-
Shallow anterior chamber	0	0	-
Choroidal detachment	0	1 (2.3)	0.40

It is made available under a CC-BY 4.0 International license .

15

Conjunctiva leakage	0	1 (2.3)	0.40
Hypotony maculopathy	0	0	-
Total number of complications	0	2 (4.7)	0.27

#### 231 †Pearson chi-square tests

232

#### 233 Risk factors for surgical failure by multivariate Cox proportional

#### 234 hazards model

235 The baseline characteristics, including history of cataract surgery, glaucoma diagnosis,

preoperative IOP, and number of glaucoma medications were evaluated as prognostic factors for

surgical failure (Table 4). The number of preoperative medications was a risk factor for failure to

satisfy criteria A and B in the TLE group. Glaucoma surgery with cataract surgery reduced the

risk of failure for criterion C in the EXP group. Factors not significantly associated with target

240	IOP succes	s rates included p	eoperative IOP,	lens status,	and diagnosis.
-----	------------	--------------------	-----------------	--------------	----------------

241

242

243

244

245

**246** Table 4. Multivariate Cox proportional hazard ratios for risk factors for failure.

EXP										
	Criterion A		Criterion B				Criterion C	2		
	5 mm	$Hg \le IOP \le$	18 mmHg	5 mm	$5 \text{ mmHg} \le \text{IOP} \le 15 \text{ mmHg}$			$5 \text{ mmHg} \le \text{IOP} \le 12 \text{ mmHg}$		
	Risk Ratio	P value	95% CI	<b>Risk Ratio</b>	P value	95% CI	Risk Ratio	P value	95% CI	
With/without cataract surgery										
EXP with catarct surgery	0.26	0.17	0.04-1.74	0.18	0.07	0.03-1.19	0.11	0.01	0.02-0.62	
EXP only	1.00			1.00			1.00			
Diagnosis										
PXG	2.83	0.22	0.52-15.35	2.90	0.19	0.60–14.34	3.20	0.09	0.84-12.29	
POAG	1.00			1.00			1.00			
Lens status										
Pseudophakia	0.52	0.60	0.05-5.80	0.21	0.16	0.03-1.77	0.30	0.15	0.06-1.56	
Phakia	1.00			1.00			1.00			
Preoperative IOP	0.86	0.18	0.67-1.03	1.05	0.37	0.93-1.16	1.10	0.06	0.99–1.22	
No. of glaucoma medication	2.24	0.18	0.74–7.94	1.09	0.83	0.50-2.65	1.53	0.23	0.78-3.29	
TLE										
		Criterion	A		Criterion I	3		Criterion C	2	
	5 mm	$Hg \le IOP \le$	18 mmHg	$5 \text{ mmHg} \le \text{IOP} \le 15 \text{ mmHg}$		$5 \text{ mmHg} \le \text{IOP} \le 12 \text{ mmHg}$				
	Risk Ratio	P value	95% CI	<b>Risk Ratio</b>	P value	95% CI	Risk Ratio	P value	95% CI	
With/without cataract surgery										
TLE with catarct surgery	1.58	0.50	0.42-6.00	1.42	0.59	0.38-5.28	1.02	0.97	0.34-3.05	
TLE only	1.00			1.00			1.00			
Diagnosis										
PXG	0.41	0.31	0.07-2.31	0.33	0.18	0.06-1.67	0.64	0.44	0.21-1.98	
POAG	1.00			1.00			1.00			
Lens status										
Pseudophakia	0.70	0.69	0.12-3.94	0.62	0.57	0.12-3.26	0.87	0.74	0.22–2.92	
Phakia	1.00			1.00			1.00			
Preoperative IOP	0.12	0.25	0.84-1.02	0.97	0.48	0.89-1.04	1.01	0.74	0.95-1.06	
No. of glaucoma medication	6.31	0.04	1.11-7.13	2.68	0.03	1.19–7.65	1.52	0.20	0.83 - 3.05	

17

- 247 CI, Confidence interval; EXP, Ex-PRESS; IOP, intraocular pressure; POAG, primary open angle glaucoma; PXG, pseudo exfoliative
- 248 glaucoma; SD, standard deviation; TLE, trabeculectomy

249

It is made available under a CC-BY 4.0 International license .

#### Discussion 250

251

Most previous studies defined successful TLE or EXP as a postoperative IOP of 18 mmHg or 252 less. However, the Advanced Glaucoma Intervention Study reported that visual field impairment 253 progressed unless the IOP was maintained at < 12.3 mmHg [8], and subjects with NTG often 254 have IOP values < 18 mmHg. Therefore, in this study, we set the target IOP at several lower 255 levels (criteria B and C). 256 Filtering surgery, including TLE, is a common and standard modality for patients with long-257 standing glaucoma. While we expected EXP to reduce IOP as effectively as TLE, based on 258 previous studies [3-4,12], an equivalent efficacy has not been demonstrated for lower target IOP 259 ranges. As the baseline IOP of some patients was in the normal range under maximum medical 260 therapy, some studies have used the percentage reduction from baseline as an outcome metric in 261 addition to absolute IOP levels. However, this criterion is not applicable in all situations. In the 262 Japanese population, NTG accounts for the majority of glaucoma cases [10]. Low preoperative 263 IOP as in NTG makes it difficult to achieve a 20% reduction from baseline after filtering surgery 264 without complications [13-14]. Therefore, only patients with IOP  $\geq$  15 mmHg were included in 265 this study.

266 Several previous prospective studies have compared the success rate of TLE to EXP both with

267 and without the use of glaucoma medications. Gonzalez-Rodriguez et al [4] defined surgical

268 success as  $5 \leq IOP \leq 18$  (criterion A in our study) and a 20% reduction from baseline, and

269 reported success rates of 59% and 76% for EXP and TLE groups, respectively, at 24 months and

270 52% and 61%, respectively, at 36 months. In accord with our results using criterion A, these

271 rates did not differ between procedures.

19

272 Most previous studies have found no difference in the number of glaucoma medications required 273 by patients following EXP or TLE [4,5,15-17], while a few have reported that the EXP group 274 required fewer glaucoma medications [3,18] and one that patients required more medications 275 following Ex-PRESS implantation [19]. In the current study, we found no significant difference 276 in the number of glaucoma medications required before or after surgery. However, the EXP 277 group required more glaucoma medications than the TLE group post surgery, and the group 278 difference in the number of eye drops required increased gradually during follow-up. Thus, it is 279 likely that the EXP group will eventually require a significantly greater number or significantly 280 higher doses of glaucoma medications.

281 We found little difference in complication rates following EXP or TLE. One patient in the TLE 282 group developed cataract, which resulted in loss of VA during the observation period, while 283 there were no cases of cataract progression in the EXP group. Similarly, Beltran-Agullo and 284 colleagues reported that cataract progression was more frequent following TLE than EXP [20], 285 potentially because EXP does not require peripheral iridectomy and thus carries a lower risk of 286 hypotony. Aqueous flare elevation may occur during or following filtration surgery due to 287 disruption of the blood-aqueous barrier, and flare severity increases with inflammatory activity 288 in the anterior segment [21]. One case study reported substantial flare on the first day after EXP 289 that subsided by the third day [22], while another reported elevated flare at 4 weeks after TLE 290 [23]. The more sustained flare after TLE may also result from iridectomy. Further, the reduced 291 inflammation following EXP may prevent cataract progression. Moreover, Arimura and 292 colleagues [16] reported a significantly greater total number of complications following TLE 293 than following EXP. However, other studies have reported similar incidences of most early 294 complications with the exception of hyphema [24]. In the current study as well, there were no

It is made available under a CC-BY 4.0 International license .

20

295	significant differences in early and late postoperative complications between treatment groups.
296	No late complications due to hypotony, such as hypotony maculopathy and choroidal
297	detachment, were observed in the EXP group. However, one case in the TLE group exhibited
298	choroidal detachment related to over filtration and low IOP. We assume that this is because EXP
299	surgery creates a constant aqueous outflow route. From this, we expect that EXP is more suitable
300	for patients at risk for complications related to low IOP. For example, young patients with long
301	axial length tend to develop hypotony maculopathy after TLE [25], which could lead to a
302	reduction in VA.

303 A Cox regression model identified the number of glaucoma medications before surgery as a risk 304 factor for surgical failure in the TLE group, consistent with previous studies [26-27] and 305 suggesting that preservatives of glaucoma medication increase the risk of TLE failure [28]. 306 Postoperative subconjunctival fibrosis after ophthalmic surgery results in increased numbers of 307 conjunctival fibroblasts and inflammatory cells [29], and preservatives will further increase the 308 number of conjunctival fibroblasts and macrophages while reducing the number of conjunctival 309 goblet cells [28]. These alterations lead to production of predisposition to heal the fistula 310 drainage, resulting in uncontrolled IOP [26,28]. Since the role of the conjunctiva is the same in 311 TLE and EXP, it can be expected that glaucoma medication will reduce the surgical success of 312 EXP through similar mechanisms. However, the number of glaucoma medications was not a risk 313 factor for EXP failure in this study. EXP does not require iridectomy and leads to less bleeding 314 and inflammatory cell infiltration. As a result, fibrosis of the conjunctiva may be prevented after 315 EXP, reducing the risk of surgical failure.

316 C	One limitation	of this study	is the group	imbalance and	l relatively sma	ll number of patients
-------	----------------	---------------	--------------	---------------	------------------	-----------------------

- because we exclude patients with preoperative IOP < 15 mmHg after randomization. We
- 318 followed patients for 3 years in this study. The number of dropout patients increased with long-
- term follow-up, which is another limitation of this study. As glaucoma requires lifelong
- 320 treatment, longer-term clinical follow is required.
- 321 In conclusion, no differences in surgical success, IOP, VA, and failure rates were noted between

322 the EXP and TLE groups in this study. We also found that the number of glaucoma medications

323 was a risk factor for surgical failure in the TLE group but not the EXP group.

324

# 325 Acknowledgments

326 The authors would like to thank Enago (www.enago.jp) for the English language review

327

328

It is made available under a CC-BY 4.0 International license .

# 329 **References**

Borisuth NS, Phillips B, Krupin T. The risk profile of glaucoma filtration surgery. Curr
 Opin Ophthalmol. 1999;10: 112-116.

332 2. Sugimoto Y, Mochizuki H, Ohkubo S, Higashide T, Sugiyama K, Kiuchi Y.

333 Intraocular pressure outcomes and risk factors for failure in the collaborative bleb-related

infection incidence and treatment study. Ophthalmology. 2015;122: 2223-2233.

335 3. de Jong L, Lafuma A, Aguadé AS, Berdeaux G. Five-year extension of a clinical trial

336 comparing the EX-PRESS glaucoma filtration device and trabeculectomy in primary open-angle

337 glaucoma. Clin Ophthalmol. 2011;5: 527-533.

338 4. Gonzalez-Rodriguez JM, Trope GE, Drori-Wagschal L, Jinapriya D, Buys YM.

339 Comparison of trabeculectomy versus Ex-PRESS: 3-year follow-up. Br J Ophthalmol. 2016;100:

**340** 1269-1273.

341 5. Wagschal LD, Trope GE, Jinapriya D, Jin YP, Buys YM. Prospective randomized

342 study comparing Ex-PRESS to trabeculectomy: 1-year results. J Glaucoma. 2015;24: 624-629.

343 6. de Moraes CG, Liebmann JM, Medeiros FA, Weinreb RN. Management of advanced
344 glaucoma: Characterization and monitoring. Surv Ophthalmol. 2016;61: 597-615.

345 7. Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open-angle
346 glaucoma blindness. Acta Ophthalmol. 2014;92: 421-425.

347 8. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between
348 control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J
349 Ophthalmol. 2000;130: 429-440.

350 9. Husain R, Clarke JCK, Seah SKL, Khaw PT. A review of trabeculectomy in East
351 Asian people--the influence of race. Eye (Lond). 2005;19: 243-252.

352	10.	Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of
353	primary o	open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111: 1641-

**354** 1648.

- 355 11. Shaarawy T, Sherwood M, Grehn F. *Guidelines on Design and Reporting of Glaucoma*356 *Surgical Trials*. Kugler Publications; 2009.
- 357 12. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC, et al.
- 358 Surgical complications in the tube versus trabeculectomy study during the first year of follow-up.
- 359 Am J Ophthalmol. 2007;143: 23-31.
- 360 13. Yuasa Y, Sugimoto Y, Hirooka K, Ohkubo S, Higashide T, Sugiyama K, et al.

361 Effectiveness of trabeculectomy with mitomycin C for glaucomatous eyes with low intraocular

362 pressure on treatment eye drops. Acta Ophthalmol. 2020;98: e81-e87.

363 14. Schultz SK, Iverson SM, Shi W, Greenfield DS. Safety and efficacy of achieving

364 single-digit intraocular pressure targets with filtration surgery in eyes with progressive normal-

- tension glaucoma. J Glaucoma. 2016;25: 217-222.
- 366 15. Moisseiev E, Zunz E, Tzur R, Kurtz S, Shemesh G. Standard trabeculectomy and Ex-

367 PRESS miniature glaucoma shunt: A comparative study and literature review. J Glaucoma.

**368** 2015;24: 410-416.

369 16. Arimura S, Miyake S, Iwasaki K, Gozawa M, Matsumura T, Takamura Y, et al.

370 Randomised clinical trial for postoperative complications after Ex-PRESS implantation versus

trabeculectomy with 2-year follow-up. Sci Rep. 2018;8: 16168.

372 17. Netland PA, Sarkisian SR, Moster MR, Ahmed II, Condon G, Salim S, et al.

373 Randomized, prospective, comparative trial of EX-PRESS glaucoma filtration device versus

trabeculectomy (XVT study). Am J Ophthalmol. 2014;157: 433-440.e3.

It is made available under a CC-BY 4.0 International license .

375	18.	Dahan E, Ben Simon GJ, Lafuma A. Comparison of trabeculectomy and Ex-PRESS				
376	implantation in fellow eyes of the same patient: a prospective, randomised study. Eye (Lond).					
377	2012;26:	2012;26: 703-710.				
378	19.	Hashimoto Y, Michihata N, Matsui H, Fushimi K, Yasunaga H, Aihara M.				
379	Reoperation rates after Ex-PRESS versus trabeculectomy for primary open-angle or normal-					
380	tension glaucoma: a national database study in Japan. Eye (Lond). 2020;34: 1069-1076.					
381	20.	Beltran-Agullo L, Trope GE, Jin Y, Wagschal LD, Jinapriya D, Buys YM. Comparison				
382	of visual	recovery following ex-PRESS versus trabeculectomy: results of a prospective				
383	randomiz	zed controlled trial. J Glaucoma. 2015;24: 181-186.				
384	21.	Sawa M. Laser flare-cell photometer: principle and significance in clinical and basic				
385	ophthalmology. Jpn J Ophthalmol. 2017;61: 21-42.					
386	22.	Ishida K, Moroto N, Murata K, Yamamoto T. Effect of glaucoma implant surgery on				
387	intraocul	ar pressure reduction, flare count, anterior chamber depth, and corneal endothelium in				
388	primary o	open-angle glaucoma. Jpn J Ophthalmol. 2017;61: 334-346.				
389	23.	Inatani M, Ogata-Iwao M, Takihara Y, Iwao K, Inoue T, Kasaoka N, et al. A				
390	prospecti	ve study of postoperative aqueous flare in trabeculectomy alone versus				
391	phacotral	peculectomy. Nippon Ganka Gakkai Zasshi. 2012;116: 856-861.				
392	24.	Wang W, Zhang X. Meta-analysis of randomized controlled trials comparing EX-				
393	PRESS in	mplantation with trabeculectomy for open-angle glaucoma. PLoS ONE. 2014;9:				
394	e100578.					
395	25.	Sakamoto M, Matsumoto Y, Mori S, Ueda K, Inoue Y, Kurimoto T, et al. Excessive				
396	scleral sh	rinkage, rather than choroidal thickening, is a major contributor to the development of				
397	hypotony	maculopathy after trabeculectomy. PLoS ONE. 2018;13: e0191862.				

- 398 26. Issa de Fendi L, Cena de Oliveira T, Bigheti Pereira C, Pereira Bigheti C, Viani GA.
- 399 Additive effect of risk factors for trabeculectomy failure in glaucoma patients: A risk-group from
- 400 a cohort study. J Glaucoma. 2016;25: e879-e883.
- 401 27. Landers J, Martin K, Sarkies N, Bourne R, Watson P. A twenty-year follow-up study
- 402 of trabeculectomy: risk factors and outcomes. Ophthalmology. 2012;119: 694-702
- 403 28. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of
- 404 antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients.
- 405 Ophthalmology. 1989;96: 327-335.
- 406 29. Broadway DC, Grierson I, Hitchings RA. Local effects of previous conjunctival
- 407 incisional surgery and the subsequent outcome of filtration surgery. Am J Ophthalmol. 1998;125:
- **408** 805-818.



■EXP □TLE





